Relmada Therapeutics (RLMD) Long-Term Debt Issuances (2017 - 2018)
Relmada Therapeutics (RLMD) reported Long-Term Debt Issuances of $26700.0 for Q1 2018, down 98.92% on a QoQ basis from $2.5 million in Q4 2017.
Relmada Therapeutics (RLMD) has 2 years of Long-Term Debt Issuances data on file, last reported at $26700.0 in Q1 2018.
- Quarterly Long-Term Debt Issuances changed N/A year-over-year to $26700.0 in Q1 2018, while the trailing twelve-month figure through Jun 2018 was $6.5 million (changed N/A YoY) and the FY2018 annual result came in at $6.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances eased to $26700.0 in Q1 2018 per RLMD's latest filing, from $2.5 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $4.0 million in Q3 2017 and bottomed at $26700.0 in Q1 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 26,700.00 |
| Mar 31, 2018 | 26,700.00 |
| Dec 31, 2017 | 2.47 Mn |
| Dec 31, 2017 | 2.47 Mn |
| Sep 30, 2017 | 4.04 Mn |
| Sep 30, 2017 | 4.04 Mn |